Issues and promises of bevacizumab in prostate cancer treatment

Expert Opinion on Biological Therapy
Vittore CeredaMario Roselli

Abstract

There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients. Until now, the drug has demonstrated anti-tumoral activity although with no improvements in overall survival (OS) and a wide range of alarming side effects in metastatic castration-resistant prostate cancer (mCRPC). Recently, promising results were achieved, using bevacizumab in combination with androgen deprivation therapy (ADT) in patients with recurrent prostate cancer after definitive local therapy. Expert opinion: The suboptimal efficacy of bevacizumab may relate to molecular events triggered during disease progression, such as redundancy of angiogenic factors or the interfering influence of androgens on ...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Apr 20, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hannes SteinerZ Culig
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shahrokh F ShariatKevin M Slawin
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phillip G FebboWilliam K Oh
Sep 7, 2006·Endocrine-related Cancer·K S Kimbro, J W Simons
Sep 15, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henk M W VerheulEmile E Voest
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyMark Kozloff
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert GrayRobert L Comis
Jan 15, 2010·The Journal of Experimental Medicine·Daniel P SievekingMartin K C Ng
Feb 27, 2010·American Journal of Hypertension·Vishal RanpuraShenhong Wu
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yang-Min NingWilliam L Dahut
Aug 7, 2010·The Oncologist·Filis Kazazi-HyseniJan H M Schellens
Jun 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C-N HuangB-Y Bao
Oct 7, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CortesJ Baselga
Nov 9, 2011·Nature Medicine·Sara M Weis, David A Cheresh
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter S Nelson
Jan 3, 2012·International Journal of Radiation Oncology, Biology, Physics·Jacqueline VukyGuobin Song
Mar 15, 2012·Expert Opinion on Therapeutic Targets·Emmanuel S Antonarakis, Michael A Carducci
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyEric J Small
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanAlfred I Neugut
Sep 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul G CornNora Navone
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal

❮ Previous
Next ❯

Citations

Jun 4, 2019·International Journal of Molecular Sciences·Zsombor Melegh, Sebastian Oltean
Jun 7, 2020·International Journal of Molecular Sciences·Milad AshrafizadehGautam Sethi
Jan 2, 2019·International Journal of Molecular Sciences·Apoorva S Iyer, Svetlana P Chapoval
Dec 29, 2020·Frontiers in Cell and Developmental Biology·Jinan GuoChang Zou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Expert Opinion on Biological Therapy
Alexander C Small, William K Oh
Future Oncology
Francesco Caprioni, Giuseppe Fornarini
The New England Journal of Medicine
Krishnansu S TewariBradley J Monk
Women's Health
Shari B GoldfarbMaura Dickler
© 2022 Meta ULC. All rights reserved